“…The mechanistic role that EPHB4 plays in cancer remains controversial. However, a preponderance of data indicate that EPHB4 is overexpressed broadly in human cancers, including cancers of the head and neck, prostate, bladder, ovaries, large intestine, lung, brain, pancreas, and esophagus (46)(47)(48)(49)(50)(51)(52)(53)(54). Further research has shown that the ablation or inhibition of EPHB4 in a number of cancer cell types reduces tumor cell viability, including prostate (47), bladder (48), ovarian (49), colon (50), lung (51), head and neck squamous cell carcinoma (74), and esophageal (54) cancer.…”